This report analyzes the MFDS IND approval status for April 2025. We reviewed 50 investigational new drug (IND) approvals issued by South Korea’s Ministry of Food and Drug Safety (MFDS) between 1 April and 30 April 2025. Aimed at domestic and international pharmaceutical and biotechnology professionals, this article summarizes the number of approvals by phase, the proportion of domestic versus overseas developments, major sponsors and therapeutic trends, and the characteristics of Korea’s clinical‑trial environment. Calls to action for quotation requests and newsletter subscriptions are included.
Approval Numbers and Phase Distribution
In April, MFDS approved a total of 50 clinical‑trial plans. Phase 3 trials accounted for 19 approvals, followed by Phase 1 (14), Phase 1/2 (nine), Phase 2 (four), Phase 2b (two), and one each for Phase 3b and Phase 2a. The dominance of Phase 3 approvals (38%) over Phase 1 (28%) and Phase 1/2 (18%) suggests that many drug candidates are progressing into late development stages. Compared with earlier months, the higher share of late‑stage trials signals a maturing pipeline in Korea.
Proportion by Development Region
Of the 50 approvals, 31 (62%) were for overseas development projects and 19 (38%) for domestic projects. The high share of overseas projects is largely due to Korea’s highly standardized infrastructure, which is backed by strong government support. Approximately 200 hospitals have been certified by MFDS as trial sites, many of them tertiary hospitals with abundant patient resources. Since becoming a full member of the International Council for Harmonisation (ICH) in 2016, Korea has strengthened its quality‑management system and maintained a spotless record in FDA inspections, making it an attractive early development hub for global sponsors. This institutional foundation and global trust explain why foreign companies actively conduct trials in Korea.
Major Sponsors and Therapeutic Trends
Among sponsors, Icon Clinical Research Korea, Celltrion, Pfizer Korea, Roche Korea, MSD Korea, Pharmaceutical Research Associates Korea, Novartis Korea, Dong‑A ST, Fortria Korea and Aju Pharmaceutical each secured two IND approvals. Oncology dominated with 20 approvals, followed by inflammatory/autoimmune diseases such as ulcerative colitis and Crohn’s disease (five), metabolic conditions like type 2 diabetes (one), and rare diseases including IgA nephropathy and hepatocellular carcinoma (one each). The remaining 23 approvals were early safety or pharmacokinetic studies in healthy volunteers or exploratory programs for various indications. While oncology remains the leading focus, diversification into autoimmune, metabolic and rare diseases indicates a broadening portfolio.
Characteristics of Korea’s Clinical‑Trial Environment and Regulation
Launching a clinical trial in Korea requires both MFDS IND approval and institutional review board (IRB) approval. MFDS reviews IND submissions within 30 business days and typically completes the process within four to six weeks. IRB reviews proceed in parallel and, thanks to the recent adoption of a central IRB system, multi‑center studies can secure ethics approval more quickly. MFDS has continually improved its processes by decoupling IND reviews from new‑drug applications, shortening the review window to 30 days in 2002 and introducing pre‑IND meetings in 2019 to encourage early consultation. As a result, Korea’s regulatory lead time averages around eight weeks—much faster than Japan’s 10–12 weeks or China’s 12–16 weeks—and some oncology Phase 2 trials have achieved IND approval in just seven weeks. These swift approvals, combined with strict Good Clinical Practice compliance and high data quality, make Korea a competitive clinical‑trial hub and encourage foreign sponsors to collaborate with domestic CROs.
Conclusion and Outlook
The April IND approval data underscore quantitative and qualitative growth in Korea’s clinical‑trial landscape. With 50 approvals and a high proportion of Phase 3 studies, the drug‑development pipeline appears to be advancing rapidly. The prevalence of overseas projects reflects active participation by global sponsors, offering opportunities for local institutions and CROs to form partnerships. Oncology remains dominant, but increasing activity in autoimmune, metabolic and rare diseases suggests diversification. Korea’s strict regulation, fast review timelines, rich patient resources and high‑quality data position the country as a global clinical‑trial hub.
We encourage pharmaceutical and biotech professionals to use these insights to refine their development strategies and explore the advantages of running trials in Korea. Take advantage of our quotation request service to discuss project budgets and timelines, and subscribe to our newsletter to stay informed about regulatory changes and approval trends. A detailed Excel list of April approvals is provided separately on our website.
